Activation of distinct cAMP- and cGMP-dependent pathways by relaxant agents in isolated gastric muscle cells.
The mechanism of action of vasoactive intestinal peptide (VIP) was examined in isolated gastric and taenia coli muscle cells and compared with that of nitric oxide (NO), sodium nitroprusside (SNP), and isoproterenol. In gastric muscle cells, VIP stimulated NO production, increased adenosine 3',5'-cyclic monophosphate (cAMP) and guanosine 3',5'-cyclic monophosphate (cGMP) levels, and induced relaxation in a concentration-dependent fashion. The NO synthase inhibitor NG-nitro-L-arginine abolished NO and cGMP production and partly inhibited relaxation. The soluble guanylate cyclase inhibitor LY 83583 abolished cGMP production and partly inhibited relaxation. (R)-p-adenosine 3',5'-cyclic phosphorothioate [(R)-p-cAMPS], a preferential inhibitor of cAMP-dependent protein kinase (cAK), and KT5823, a preferential inhibitor of cGMP-dependent protein kinase (cGK), partly inhibited relaxation separately and abolished relaxation in combination. The pattern implied that VIP induced relaxation by activation of cAK and by NO-mediated stimulation of cGMP and activation of cGK. In taenia coli muscle cells, VIP did not increase NO production or cGMP levels: relaxation was accompanied by an increase in cAMP and was partly inhibited by (R)-p-cAMPS and KT5823 and abolished by a combination of both inhibitors. Isoproterenol increased only cAMP levels in both cell types, which induced relaxation by activating cAK at low concentrations of agonist and both cAK and cGK at high concentrations in a pattern identical to that observed with VIP in taenia coli muscle cells. SNP and NO increased only cGMP levels in both cell types, which induced relaxation by activating cGK only. We conclude that cAK and cGK can be activated separately and mediate relaxation independently.(ABSTRACT TRUNCATED AT 250 WORDS)
Jin
J G
JG
Department of Medicine, Medical College of Virginia, Richmond 23298-0711.
Murthy
K S
KS
Grider
J R
JR
Makhlouf
G M
GM
D000634:Aminoquinolines / Q000494:pharmacology; D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives / Q000494:pharmacology; D002469:Cell Separation; D003106:Colon / Q000166:cytology / Q000502:physiology; D000242:Cyclic AMP / Q000378:metabolism / Q000502:physiology*; D006152:Cyclic GMP / Q000378:metabolism / Q000502:physiology*; D004064:Digestive System / Q000166:cytology*; D004068:Digestive System Physiological Phenomena; D004789:Enzyme Activation / Q000187:drug effects / Q000502:physiology; D005748:Gastric Fundus / Q000166:cytology / Q000502:physiology; D006168:Guinea Pigs; D007545:Isoproterenol / Q000494:pharmacology*; D009126:Muscle Relaxation / Q000187:drug effects / Q000502:physiology*; D009132:Muscles / Q000166:cytology* / Q000502:physiology; D009566:Nitrates / Q000378:metabolism / Q000494:pharmacology*; D017942:Nitric Acid; D019335:Nitroarginine; D009599:Nitroprusside / Q000494:pharmacology*; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000502:physiology; D013189:SRS-A / Q000037:antagonists & inhibitors; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology*
D000634:Aminoquinolines; D009566:Nitrates; D013189:SRS-A; D009599:Nitroprusside; D019335:Nitroarginine; D014660:Vasoactive Intestinal Peptide; D017942:Nitric Acid; C041715:6-anilino-5,8-quinolinedione; D001120:Arginine; D000242:Cyclic AMP; D011493:Protein Kinase C; D006152:Cyclic GMP; D007545:Isoproterenol